QUILT-2.021: Randomized Study of Single Course of Intraperitoneal (IP) ALT-803 Followed by Subcutaneous (SQ) Maintenance ALT-803 Versus Subcutaneous (SQ) Maintenance ALT-803 Only After 1st Line Chemotherapy for Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Phase of Trial: Phase I
Latest Information Update: 15 Jun 2018
Price : $35 *
At a glance
- Drugs ALT 803 (Primary) ; ALT 803 (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 20 Oct 2017 Status changed from not yet recruiting to recruiting.
- 13 Jun 2017 Planned initiation date changed from 1 May 2017 to 1 Aug 2017.
- 20 Feb 2017 New trial record